No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension.


Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
29 01 2021
Historique:
received: 01 10 2020
revised: 27 12 2020
accepted: 06 01 2021
pubmed: 7 1 2021
medline: 21 8 2021
entrez: 6 1 2021
Statut: ppublish

Résumé

Brain renin-angiotensin system (RAS) activation is thought to mediate deoxycorticosterone acetate (DOCA)-salt hypertension, an animal model for human primary hyperaldosteronism. Here, we determined whether brainstem angiotensin II is generated from locally synthesized angiotensinogen and mediates DOCA-salt hypertension. To this end, chronic DOCA-salt-hypertensive rats were treated with liver-directed siRNA targeted to angiotensinogen, the angiotensin II type 1 receptor antagonist valsartan, or the mineralocorticoid receptor antagonist spironolactone (n = 6-8/group). We quantified circulating angiotensinogen and renin by enzyme-kinetic assay, tissue angiotensinogen by Western blotting, and angiotensin metabolites by LC-MS/MS. In rats without DOCA-salt, circulating angiotensin II was detected in all rats, whereas brainstem angiotensin II was detected in 5 out of 7 rats. DOCA-salt increased mean arterial pressure by 19 ± 1 mmHg and suppressed circulating renin and angiotensin II by >90%, while brainstem angiotensin II became undetectable in 5 out of 7 rats (<6 fmol/g). Gene silencing of liver angiotensinogen using siRNA lowered circulating angiotensinogen by 97 ± 0.3%, and made brainstem angiotensin II undetectable in all rats (P<0.05 vs. non-DOCA-salt), although brainstem angiotensinogen remained intact. As expected for this model, neither siRNA nor valsartan attenuated the hypertensive response to DOCA-salt, whereas spironolactone normalized blood pressure and restored brain angiotensin II together with circulating renin and angiotensin II. In conclusion, despite local synthesis of angiotensinogen in the brain, brain angiotensin II depended on circulating angiotensinogen. That DOCA-salt suppressed circulating and brain angiotensin II in parallel, while spironolactone simultaneously increased brain angiotensin II and lowered blood pressure, indicates that DOCA-salt hypertension is not mediated by brain RAS activation.

Identifiants

pubmed: 33404046
pii: 227513
doi: 10.1042/CS20201239
doi:

Substances chimiques

Sodium Chloride, Dietary 0
Angiotensinogen 11002-13-4
Angiotensin II 11128-99-7
Desoxycorticosterone Acetate 6E0A168OB8
Valsartan 80M03YXJ7I
Renin EC 3.4.23.15

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-274

Informations de copyright

© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Estrellita Uijl (E)

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

Liwei Ren (L)

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Translational Medicine Collaborative Innovation Center, The Second Clinical Medical College (Shenzhen People's Hospital) of Jinan University, Shenzhen, China.
Department of Physiology, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China.

Katrina M Mirabito Colafella (KM)

Cardiovascular Program, Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Australia.

Richard van Veghel (R)

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

Ingrid M Garrelds (IM)

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

Oliver Domenig (O)

Attoquant Diagnostics, Vienna, Austria.

Marko Poglitsch (M)

Attoquant Diagnostics, Vienna, Austria.

Ivan Zlatev (I)

Alnylam Pharmaceuticals, Cambridge, MA, U.S.A.

Jae B Kim (JB)

Alnylam Pharmaceuticals, Cambridge, MA, U.S.A.

Stephen Huang (S)

Alnylam Pharmaceuticals, Cambridge, MA, U.S.A.

Lauren Melton (L)

Alnylam Pharmaceuticals, Cambridge, MA, U.S.A.

Ewout J Hoorn (EJ)

Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

Don Foster (D)

Alnylam Pharmaceuticals, Cambridge, MA, U.S.A.

A H Jan Danser (AHJ)

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH